Hot Investor Mandate: Venture Capital Firm Partners With Hospitals to Launch New Medical Technologies

31 Oct

A Venture Capital firm specializing in technologies, financials and healthcare industries has an investment management team that includes many experts and experienced professionals from hospitals and healthcare systems.  The firm has partnered with premier hospitals in the US, Taiwan and China to introduce new technologies.

The investment strategy of the firm has three main sectors: Greater China’s healthcare reform opportunities, disruptive medical technologies & business models, and synergies with their domestic and foreign hospital & medical network.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Global Technology Corporation Invests in Software-Enabled Devices

31 Oct

The healthcare and life sciences branch of a global technology corporation and manufacturing company looks to invest primarily in Series A or later companies in digital health, medical devices, genomics and molecular diagnostics technologies, but can expand their focus conditionally. While some of their investments are strategic to the parent company, the firm is willing to invest outside of corporate strategic areas. The firm is a global investor, and can act as both a strategic partner and a financial investor, depending on the company.

The firm can invest as a strategic manufacturing company, but is also interested in software-enabled technologies and connected devices. While the firm may consider PMA devices, most investments are in 510k-pathway products. For purely digital health products, such as IoT technology, the firm would like to see some revenue and market traction before investing. For both medical devices and digital health, the firm is agnostic to indication. Firm’s interest in genomics and molecular diagnostics primarily relate to the oncology space, and prefer to see technologies with some clinical data.

The firm may take a board seat after investing, if they are the lead or if they have strategic value to offer the portfolio company, but will generally not take a board seat if they are co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Japan Private Equity Looking Globally for Therapeutics, Devices and Digital Medicine

31 Oct

A private equity firm based in Japan makes venture stage investments, with  a typical investment size of USD 3-5 million per company. The firm’s geographical focus is Asia, centered on Japan and Taiwan. However, the firm may consider companies in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm will primarily focus on therapeutics, and is also interested in medical devices and digital medicine. The firm is interested in new technologies such as cell and gene therapies, but also considers investing in small molecules and biologics, as well as biosimilars and reformulated drugs. The firm will invest in any indication area. The firm invests in companies from the late preclinical stage through to Phase II.

The firm is usually a follow-on investor. For early stage opportunities, the firm prefers that the company has a clinical trial plan in place. While the firm is interested in international opportunities, they prefer that the company is interested in expanding into Japan or Taiwan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Angel Fund Makes Seed and Pre-A Round Investments

31 Oct

A biotech angel investment fund founded in 2016 and headquartered in Taiwan has a fund size of $50M and an average ticket size range from $250K to $1M. The fund mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI Asia Partnering Launches Monday, October 28th

24 Oct

By Karen Deyo, Senior Investor Research Analyst, LSN

The partnering platform has always been one of the main differentiators of the RESI Conference. Powered by the LSN Investor Platform, the detailed investor profiles that allow companies to book one-on-one meetings with partners who are a fit for them streamlines the process and improves the quality of the meetings that take place at RESI. The partnering platform allows attendees to filter by sector, stage of development, indication, among other factors, to find only those investors and strategic partners who are looking for technologies like theirs. Once an attendee requests a meeting, and the recipient has accepted it, the partnering platform will automatically assign a time and a table for the meeting to take place. Starting on Monday, Oct. 28th, attendees of RESI Asia will be able to take advantage of this system to book up to 16 high-quality one-on-one meetings. If you are interested in learning tips on how to make the best use of the partnering platform, here are a few articles that can help:

Confirmed RESI Asia Investors

VIVA Biotech, Shanghai, China based CRO will be the Innovation Challenge Gold Sponsor for RESI

24 Oct

By Candice He, Global Investment Strategist, LSN

After supporting the RESI Conference Series with delegates and speakers for many years, VIVA Biotech has become a Gold Sponsor of RESI Shanghai and RESI San Francisco.  At RESI, you will be able to meet with VIVA’s delegation of elite portfolio companies, and with top expert speakers representing VIVA at RESI’s panels and pitch sessions. You will also have the opportunity to meet with VIVA during RESI’s cocktail party, where VIVA will present the awards for the RESI Innovation Challenge!  Finally, RESI Shanghai attendees will also have the opportunity to take a tour of VIVA Biotech’s incubator.  We hope you will join us and our sponsors and partners at RESI Shanghai.

About VIVA Biotech

Viva Biotech’s mission is to become a cradle for innovative biotechnology companies around the world. Viva Biotech has developed a scalable business model combing the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model. Under the CFS model, the Group provides structure-based drug discovery services to its biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development, covering the full spectrum of the customers’ needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. Viva Biotech also provides drug discovery and incubation services to biotechnology start-up companies with high potential under its EFS model. As of June 30, 2019, Viva Biotech had provided drug discovery services to 388 biotechnology and pharmaceutical customers worldwide, worked on over 1,000 independent drug targets, delivered over 11,000 independent protein structures, and incubated a total of 37 early stage R&D projects.

Supporting RESI Conferences for years, VIVA Biotech will be the Innovation Challenge Gold Sponsor for RESI Shanghai on Nov. 12th and RESI San Francisco on Nov. 14th

Exercise for Your Brain’s Health: Interview with Prof John J. Ratey, Associate Clinical Professor of Psychiatry at Harvard Medical School

24 Oct

By Lucy Parkinson, VP of Investor Research, LSN

Continuing LSN’s series of video interviews with life science thought leaders, Dennis Ford recently sat down with John J. Ratey, Associate Clinical Professor of Psychiatry at Harvard Medical School.  John’s career has focused on the role exercise can play in treating psychiatric conditions such as ADHD, depression, anxiety, addiction, and stress.  In this 12-minute interview, John talks to Dennis about how he began to focus on this connection, even as an ever greater proportion of the population adopt sedentary lifestyles.  John explores the possibility of ‘rewilding’ society to incorporate more movement and human connections to improve our mental health, and the tantalizing possibility that ‘AI coaches’ could help us reach this goal.

← Older Entries
Newer Entries →